4D Molecular Therapeutics (FDMT) Jefferies Global Healthcare Conference 2026 summary

Technology and product overview

• Lead product 4D-150 uses directed evolution to create best-in-class AAV vectors for continuous anti-VEGF expression in the retina, aiming to improve vision and reduce treatment burden in wet AMD and diabetic eye disease.

• 4D-150 delivers aflibercept directly to the retina, providing sustained therapy and potentially reducing or eliminating the need for frequent injections.

• The approach targets a paradigm shift from incremental improvements in injection intervals to potentially years-long or lifelong benefit.

Clinical development and data

• Two phase III trials (4FRONT-1 and 4FRONT-2) in wet AMD are underway; 4FRONT-1 completed enrollment in Q1 with data expected in the first half of next year, and 4FRONT-2 will complete enrollment in the second half of this year.

• Phase II PRISM study showed a 50% treatment-free rate at 52 weeks and 80%-90% reduction in treatment burden, with strong physician and patient reception.

• Efficacy was observed across severe and less severe patient populations, with up to 90% treatment burden reduction and nearly 75% injection-free at 18 months in newly diagnosed patients.

• Safety profile is favorable, with no significant adverse events and only mild, non-clinically significant inflammation in a small number of patients.

• Lifelong expression is expected due to the non-turnover of retinal tissue, supported by long-term AAV data in similar indications.

Commercial and strategic positioning

• 4D-150 is designed for seamless integration into current retina practice logistics, using standard intravitreal injection and buy-and-bill reimbursement models.

• Low dose and localized delivery result in cost of goods under $1,000, providing pricing flexibility and favorable practice economics.

• The product is positioned as a backbone therapy in a $20 billion retinal market, with potential for significant strategic interest but also scalability for independent commercialization.

• Manufacturing is established with in-house and CDMO capabilities, enabling large-scale production and stockpiling ahead of launch.